<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32690681</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>117</Volume><Issue>31</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>04</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Metformin inhibits RAN translation through PKR pathway and mitigates disease in <i>C9orf72</i> ALS/FTD mice.</ArticleTitle><Pagination><StartPage>18591</StartPage><EndPage>18599</EndPage><MedlinePgn>18591-18599</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2005748117</ELocationID><Abstract><AbstractText>Repeat associated non-AUG (RAN) translation is found in a growing number of microsatellite expansion diseases, but the mechanisms remain unclear. We show that RAN translation is highly regulated by the double-stranded RNA-dependent protein kinase (PKR). In cells, structured CAG, CCUG, CAGG, and G<sub>4</sub>C<sub>2</sub> expansion RNAs activate PKR, which leads to increased levels of multiple RAN proteins. Blocking PKR using PKR-K296R, the TAR RNA binding protein or PKR-KO cells, reduces RAN protein levels. p-PKR is elevated in <i>C9orf72</i> ALS/FTD human and mouse brains, and inhibiting PKR in <i>C9orf72</i> BAC transgenic mice using AAV-PKR-K296R or the Food and Drug Administration (FDA)-approved drug metformin, decreases RAN proteins, and improves behavior and pathology. In summary, targeting PKR, including by use of metformin, is a promising therapeutic approach for <i>C9orf72</i> ALS/FTD and other expansion diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 the Author(s). Published by PNAS.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zu</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for NeuroGenetics, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Genetics &amp; Microbiology, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genetics Institute, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Shu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for NeuroGenetics, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Genetics &amp; Microbiology, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genetics Institute, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bardhi</LastName><ForeName>Olgert</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Center for NeuroGenetics, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Genetics &amp; Microbiology, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genetics Institute, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryskamp</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0002-2197-0730</Identifier><AffiliationInfo><Affiliation>Center for NeuroGenetics, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Genetics &amp; Microbiology, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genetics Institute, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for NeuroGenetics, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Genetics &amp; Microbiology, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genetics Institute, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khoramian Tusi</LastName><ForeName>Solaleh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for NeuroGenetics, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Genetics &amp; Microbiology, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genetics Institute, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelbrecht</LastName><ForeName>Avery</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for NeuroGenetics, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Genetics &amp; Microbiology, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genetics Institute, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klippel</LastName><ForeName>Kelena</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for NeuroGenetics, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Genetics &amp; Microbiology, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genetics Institute, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakrabarty</LastName><ForeName>Paramita</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Translation Research in Neurodegenerative Disease, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Lien</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for NeuroGenetics, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Genetics &amp; Microbiology, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genetics Institute, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golde</LastName><ForeName>Todd E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Center for Translation Research in Neurodegenerative Disease, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McKnight Brain Institute, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonenberg</LastName><ForeName>Nahum</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4707-8759</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, McGill University, Montreal, A3A 1A3, Canada; nahum.sonenberg@mcgill.ca ranum@ufl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ranum</LastName><ForeName>Laura P W</ForeName><Initials>LPW</Initials><Identifier Source="ORCID">0000-0001-9808-9661</Identifier><AffiliationInfo><Affiliation>Center for NeuroGenetics, College of Medicine, University of Florida, Gainesville, FL 32610; nahum.sonenberg@mcgill.ca ranum@ufl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Genetics &amp; Microbiology, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genetics Institute, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McKnight Brain Institute, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, University of Florida, Gainesville, FL 32610.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Norman Fixel Institute for Neurological Disease, University of Florida, Gainesville, FL 32608.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 NS040389</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS058901</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D019892">eIF-2 Kinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2020 Aug 18;117(33):19627-19628</RefSource><PMID Version="1">32727895</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="Y">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018895" MajorTopicYN="N">Microsatellite Repeats</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014176" MajorTopicYN="N">Protein Biosynthesis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019892" MajorTopicYN="Y">eIF-2 Kinase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS/FTD</Keyword><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">PKR</Keyword><Keyword MajorTopicYN="N">RAN translation</Keyword><Keyword MajorTopicYN="N">metformin</Keyword></KeywordList><CoiStatement>Competing interest statement: T.Z., L.N., and L.P.W.R. are listed as inventors on patents filed by the University of Florida related to RAN translation.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32690681</ArticleId><ArticleId IdType="pmc">PMC7414156</ArticleId><ArticleId IdType="doi">10.1073/pnas.2005748117</ArticleId><ArticleId IdType="pii">2005748117</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cho D. H. et al. ., Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol. Cell 20, 483&#x2013;489 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16285929</ArticleId></ArticleIdList></Reference><Reference><Citation>Moseley M. L. et al. ., Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat. Genet. 38, 758&#x2013;769 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16804541</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T. et al. ., Non-ATG-initiated translation directed by microsatellite expansions. Proc. Natl. Acad. Sci. U.S.A. 108, 260&#x2013;265 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017129</ArticleId><ArticleId IdType="pubmed">21173221</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash P. E. et al. ., Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77, 639&#x2013;646 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K. et al. ., The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339, 1335&#x2013;1338 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T. et al. ., RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl. Acad. Sci. U.S.A. 110, E4968&#x2013;E4977 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary J. D., Ranum L. P., New developments in RAN translation: insights from multiple diseases. Curr. Opin. Genet. Dev. 44, 125&#x2013;134 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5951168</ArticleId><ArticleId IdType="pubmed">28365506</ArticleId></ArticleIdList></Reference><Reference><Citation>Green K. M. et al. ., RAN translation at C9orf72-associated repeat expansions is selectively enhanced by the integrated stress response. Nat. Commun. 8, 2005 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5722904</ArticleId><ArticleId IdType="pubmed">29222490</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng W. et al. ., C9ORF72 GGGGCC repeat-associated non-AUG translation is upregulated by stress through eIF2&#x3b1; phosphorylation. Nat. Commun. 9, 51 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5754368</ArticleId><ArticleId IdType="pubmed">29302060</ArticleId></ArticleIdList></Reference><Reference><Citation>Todd T. W., Petrucelli L., Insights into the pathogenic mechanisms of Chromosome 9 open reading frame 72 (C9orf72) repeat expansions. J. Neurochem. 138 (suppl. 1), 145&#x2013;162 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27016280</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J. P., Brown R. H. Jr., Cleveland D. W., Decoding ALS: From genes to mechanism. Nature 539, 197&#x2013;206 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Edery I., Petryshyn R., Sonenberg N., Activation of double-stranded RNA-dependent kinase (dsl) by the TAR region of HIV-1 mRNA: A novel translational control mechanism. Cell 56, 303&#x2013;312 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2536299</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian B. et al. ., Expanded CUG repeat RNAs form hairpins that activate the double-stranded RNA-dependent protein kinase PKR. RNA 6, 79&#x2013;87 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1369895</ArticleId><ArticleId IdType="pubmed">10668800</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonenberg N., Hinnebusch A. G., Regulation of translation initiation in eukaryotes: Mechanisms and biological targets. Cell 136, 731&#x2013;745 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3610329</ArticleId><ArticleId IdType="pubmed">19239892</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y. et al. ., C9orf72 BAC mouse model with motor deficits and neurodegenerative features of ALS/FTD. Neuron 90, 521&#x2013;534 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27112499</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T. et al. ., Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell 140, 338&#x2013;348 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2820414</ArticleId><ArticleId IdType="pubmed">20144759</ArticleId></ArticleIdList></Reference><Reference><Citation>Bando Y. et al. ., Double-strand RNA dependent protein kinase (PKR) is involved in the extrastriatal degeneration in Parkinson&#x2019;s disease and Huntington&#x2019;s disease. Neurochem. Int. 46, 11&#x2013;18 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15567511</ArticleId></ArticleIdList></Reference><Reference><Citation>Ba&#xf1;ez-Coronel M. et al. ., A pathogenic mechanism in Huntington&#x2019;s disease involves small CAG-repeated RNAs with neurotoxic activity. PLoS Genet. 8, e1002481 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285580</ArticleId><ArticleId IdType="pubmed">22383888</ArticleId></ArticleIdList></Reference><Reference><Citation>Dere R., Napierala M., Ranum L. P., Wells R. D., Hairpin structure-forming propensity of the (CCTG.CAGG) tetranucleotide repeats contributes to the genetic instability associated with myotonic dystrophy type 2. J. Biol. Chem. 279, 41715&#x2013;41726 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15292165</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciesiolka A., Jazurek M., Drazkowska K., Krzyzosiak W. J., Structural characteristics of simple RNA repeats associated with disease and their deleterious protein interactions. Front. Cell. Neurosci. 11, 97 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5387085</ArticleId><ArticleId IdType="pubmed">28442996</ArticleId></ArticleIdList></Reference><Reference><Citation>Benkirane M. et al. ., Oncogenic potential of TAR RNA binding protein TRBP and its regulatory interaction with RNA-dependent protein kinase PKR. EMBO J. 16, 611&#x2013;624 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1169664</ArticleId><ArticleId IdType="pubmed">9034343</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H. et al. ., TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR. Proc. Natl. Acad. Sci. U.S.A. 91, 4713&#x2013;4717 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43858</ArticleId><ArticleId IdType="pubmed">7515177</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayers J. I. et al. ., Widespread and efficient transduction of spinal cord and brain following neonatal AAV injection and potential disease modifying effect in ALS mice. Mol. Ther. 23, 53&#x2013;62 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4426802</ArticleId><ArticleId IdType="pubmed">25228069</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen L. et al. ., Antibody therapy targeting RAN proteins rescues C9 ALS/FTD phenotypes in C9orf72 mouse model. Neuron 105, 645&#x2013;662.e11 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391607</ArticleId><ArticleId IdType="pubmed">31831332</ArticleId></ArticleIdList></Reference><Reference><Citation>Barzilai N., Crandall J. P., Kritchevsky S. B., Espeland M. A., Metformin as a tool to target aging. Cell Metab. 23, 1060&#x2013;1065 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5943638</ArticleId><ArticleId IdType="pubmed">27304507</ArticleId></ArticleIdList></Reference><Reference><Citation>Gantois I., Popic J., Khoutorsky A., Sonenberg N., Metformin for treatment of fragile X syndrome and other neurological disorders. Annu Rev Med. 70, 167&#x2013;181 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30365357</ArticleId></ArticleIdList></Reference><Reference><Citation>Gantois I. et al. ., Metformin ameliorates core deficits in a mouse model of fragile X syndrome. Nat. Med. 23, 674&#x2013;677 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28504725</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma T. C. et al. ., Metformin therapy in a transgenic mouse model of Huntington&#x2019;s disease. Neurosci. Lett. 411, 98&#x2013;103 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17110029</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnoux I. et al. ., Metformin reverses early cortical network dysfunction and behavior changes in Huntington&#x2019;s disease. eLife 7, e38744 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6156080</ArticleId><ArticleId IdType="pubmed">30179155</ArticleId></ArticleIdList></Reference><Reference><Citation>Ba&#xf1;ez-Coronel M. et al. ., RAN translation in Huntington disease. Neuron 88, 667&#x2013;677 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4684947</ArticleId><ArticleId IdType="pubmed">26590344</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedersha N. L., Gupta M., Li W., Miller I., Anderson P., RNA-binding proteins TIA-1 and TIAR link the phosphorylation of eIF-2 alpha to the assembly of mammalian stress granules. J. Cell Biol. 147, 1431&#x2013;1442 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174242</ArticleId><ArticleId IdType="pubmed">10613902</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman R. J., DNA transfection to study translational control in mammalian cells. Methods 11, 361&#x2013;370 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9126551</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W. et al. ., Double-stranded RNA-dependent protein kinase-dependent apoptosis induction by a novel small compound. J. Pharmacol. Exp. Ther. 328, 866&#x2013;872 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2658620</ArticleId><ArticleId IdType="pubmed">19066342</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y. et al. ., Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer&#x2019;s amyloid peptides via up-regulating BACE1 transcription. Proc. Natl. Acad. Sci. U.S.A. 106, 3907&#x2013;3912 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656178</ArticleId><ArticleId IdType="pubmed">19237574</ArticleId></ArticleIdList></Reference><Reference><Citation>Foretz M., Guigas B., Bertrand L., Pollak M., Viollet B., Metformin: From mechanisms of action to therapies. Cell Metab. 20, 953&#x2013;966 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25456737</ArticleId></ArticleIdList></Reference><Reference><Citation>Memmott R. M. et al. ., Metformin prevents tobacco carcinogen&#x2013;Induced lung tumorigenesis. Cancer Prev. Res. (Phila.) 3, 1066&#x2013;1076 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192328</ArticleId><ArticleId IdType="pubmed">20810672</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon S. L., Sonenberg N., Parker R., Neuronal regulation of eIF2&#x3b1; function in health and neurological disorders. Trends Mol. Med. 24, 575&#x2013;589 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29716790</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu P. J. et al. ., Suppression of PKR promotes network excitability and enhanced cognition by interferon-&#x3b3;-mediated disinhibition. Cell 147, 1384&#x2013;1396 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3569515</ArticleId><ArticleId IdType="pubmed">22153080</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu P. J. et al. ., Activation of the ISR mediates the behavioral and neurophysiological abnormalities in Down syndrome. Science 366, 843&#x2013;849 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299149</ArticleId><ArticleId IdType="pubmed">31727829</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneb H. M., Sharp P. S., Rahmani-Kondori N., Wells D. J., Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice. PLoS One 6, e24189 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3164704</ArticleId><ArticleId IdType="pubmed">21909419</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou M. A. et al. ., Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: A population-based study. JAMA Neurol. 72, 905&#x2013;911 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4975611</ArticleId><ArticleId IdType="pubmed">26030836</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A. et al. ., ALS disease onset may occur later in patients with pre-morbid diabetes mellitus. Eur. J. Neurol. 17, 733&#x2013;739 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20074230</ArticleId></ArticleIdList></Reference><Reference><Citation>Herv&#xe1;s D. et al. ., Metformin intake associates with better cognitive function in patients with Huntington&#x2019;s disease. PLoS One 12, e0179283 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5478119</ArticleId><ArticleId IdType="pubmed">28632780</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassez G. et al. ., Improved mobility with metformin in patients with myotonic dystrophy type 1: A randomized controlled trial. Brain 141, 2855&#x2013;2865 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30169600</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>